Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 254-261

  Monto, A S ^a   Fleming, D M ^b   Henry, D ^c   De Groot, R ^d   Makela, M ^e,i   Klein, T ^f   Elliott, M ^g   Keene, O N ^h   Man, C Y ^h  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Northfield Health Centre   (United Kingdom)

^c Foothill Family Clinic   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f Harland Research Associates LLC   (United States)

^g GLAXOSMITHKLINE   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIALIDASE INHIBITOR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; HIGH RISK POPULATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; PYRANS; SIALIC ACIDS; TREATMENT OUTCOME; ZANAMIVIR;

EID: 0033495482     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314904     Document Type: Article

References (29)

1. 1. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987;82(Suppl 6A):20-5.
2. 2. Monto AS, Koopman JS, Longini IM Jr. Tecumseh study of illness. XIII: influenza infection and disease, 1976-1981. Am J Epidemiol 1985;121: 811-22.
3. 3. Frank AL, Taber LH, Wells JM. Comparison of infection rates and severity of illnesses and antibody response. JAMA 1967;202:494-500.
4. 4. Frank AL, Taber LH, Glezen WP, et al. Influenza B virus infections in the community and the family: the epidemics of 1976-1977 and 1979-1980 in Houston, Texas. Am J Epidemiol 1983;118:313-25.
5. 5. Sullivan KM, Monto AS, Longini IM Jr. Estimates of the US health impact of influenza. Am J Public Health 1993;83:1712-6.
6. 6. Patriarca PA, Strikas RA. Influenza vaccine for healthy adults? N Engl J Med 1995;333:933-4.
7. 7. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986;29:339-41.
8. 8. Van Voris LP, Betts RG, Hayden FG, et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981;245:1128-31.
9. 9. Younkin SW, Betts RF, Roth FK, et al. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother 1983;23: S77-82.
10. 10. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
11. 11. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995;39:2224-8.
12. 12. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin 1992;15:362-7.
13. 13. von Itzstein M, Dyason JC, Oliver SW, et al. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J Med Chemother 1996;39:388-91.
14. 14. Air GM, Laver WG. The neuraminidase of influenza virus. Protein Struc Funct Genet 1989;6:341-56.
15. 15. Woods JM, Bethell RC, Coates JAV, et al. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneruaminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993;37:1473-9.
16. 16. Hayden FG, Treanor JJ, Betts RK, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996;275:295-9.
17. 17. Hayden, FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337:874-80.
18. 18. The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in the treatment of influenza A and B virus infections. Lancet 1998;352:1877-81.
19. 19. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1993:178-201, 398-412.
20. 20. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975:81-95.
21. 21. Koch GG, Edwards S. Clinical efficacy trials with categorical data. In: Peace KE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 1988:403-57.
22. 22. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:911-8.
23. 23. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981:260-79.
24. 24. Sabin AB. Amantadine hydrochloride: analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA 1967;200:943-50.
25. 25. Centers for Disease Control and Prevention. Prevention and control of influenza. Part II. Antiviral agents -recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994;43:1-10.
26. 26. Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 1975;23:212-5.
27. 27. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991;134:988-97.
28. 28. Osterhaus A, Tisdale M, Elliott M. A double blind randomized trial of zanamivir in the treatment of acute influenza - clinical and virological efficacy results [abstract H-67]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998 (San Diego). Washington, DC: American Society for Microbiology, 1998.
29. 29. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62.